Supplementary Figures 1-2, Supplementary Tables 1-3 from Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Figure S1: Downregulation of CCR2, CD180, MYC and upregulation of HEXIM1 mRNAs by AZD5153 in cells can be detected at 4h; Figure S2: Other BRD4/BET compounds can also downregulate CCR2 and CD180 mRNAs in hematological tumor cell lines; Supplementary Table 1: Description of cell lines used in the RNAseq study; Supplementary Table 2: Information on qPCR assays used in these studies; Supplementary Table 3: More detailed information for each healthy volunteer and patient sample.